Research Analysts Set Expectations for ABEO FY2025 Earnings

Abeona Therapeutics Inc. (NASDAQ:ABEO) – Research analysts at HC Wainwright dropped their FY2025 earnings estimates for Abeona Therapeutics in a research report issued on Thursday, November 13th. HC Wainwright analyst R. Selvaraju now expects that the biopharmaceutical company will post earnings per share of $1.22 for the year, down from their previous estimate of $1.49. HC Wainwright currently has a “Buy” rating and a $20.00 target price on the stock. The consensus estimate for Abeona Therapeutics’ current full-year earnings is ($1.16) per share. HC Wainwright also issued estimates for Abeona Therapeutics’ Q4 2025 earnings at ($0.42) EPS, Q1 2026 earnings at ($0.23) EPS, Q2 2026 earnings at ($0.21) EPS, Q3 2026 earnings at ($0.02) EPS, Q4 2026 earnings at $0.03 EPS and FY2026 earnings at ($0.41) EPS.

Abeona Therapeutics (NASDAQ:ABEO) last released its earnings results on Wednesday, November 12th. The biopharmaceutical company reported ($0.10) EPS for the quarter, beating the consensus estimate of ($0.27) by $0.17.

Several other equities analysts have also issued reports on ABEO. Weiss Ratings lowered Abeona Therapeutics from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Friday, October 24th. Wall Street Zen lowered Abeona Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday. Finally, Oppenheimer upped their target price on Abeona Therapeutics from $19.00 to $20.00 and gave the company an “outperform” rating in a research note on Friday, August 15th. Four analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Abeona Therapeutics has an average rating of “Moderate Buy” and an average target price of $20.00.

Abeona Therapeutics Stock Up 1.3%

Shares of ABEO opened at $4.51 on Monday. The company has a 50-day simple moving average of $5.30 and a 200-day simple moving average of $5.96. The firm has a market capitalization of $244.40 million, a P/E ratio of 6.44 and a beta of 1.45. The company has a debt-to-equity ratio of 0.09, a quick ratio of 6.65 and a current ratio of 6.73. Abeona Therapeutics has a 52 week low of $3.93 and a 52 week high of $7.54.

Insider Buying and Selling

In other news, Director Mark Alvino sold 15,000 shares of the stock in a transaction that occurred on Thursday, November 13th. The stock was sold at an average price of $4.74, for a total value of $71,100.00. Following the completion of the transaction, the director directly owned 62,252 shares of the company’s stock, valued at approximately $295,074.48. This represents a 19.42% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, SVP Brendan M. O’malley sold 9,366 shares of the business’s stock in a transaction on Monday, September 29th. The shares were sold at an average price of $5.39, for a total value of $50,482.74. Following the completion of the sale, the senior vice president directly owned 350,763 shares in the company, valued at approximately $1,890,612.57. This represents a 2.60% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 78,612 shares of company stock valued at $410,271. 6.90% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Abeona Therapeutics

Several large investors have recently made changes to their positions in the company. Boone Capital Management LLC bought a new position in Abeona Therapeutics during the 2nd quarter valued at about $7,126,000. Geode Capital Management LLC increased its holdings in shares of Abeona Therapeutics by 129.1% during the second quarter. Geode Capital Management LLC now owns 1,105,862 shares of the biopharmaceutical company’s stock worth $6,282,000 after buying an additional 623,243 shares in the last quarter. Cable Car Capital LP bought a new position in shares of Abeona Therapeutics in the third quarter valued at approximately $3,168,000. JPMorgan Chase & Co. boosted its holdings in shares of Abeona Therapeutics by 255.6% in the 2nd quarter. JPMorgan Chase & Co. now owns 831,132 shares of the biopharmaceutical company’s stock worth $4,721,000 after acquiring an additional 597,373 shares in the last quarter. Finally, Bank of America Corp DE boosted its holdings in shares of Abeona Therapeutics by 176.7% in the 3rd quarter. Bank of America Corp DE now owns 912,912 shares of the biopharmaceutical company’s stock worth $4,820,000 after acquiring an additional 583,028 shares in the last quarter. Institutional investors own 80.56% of the company’s stock.

About Abeona Therapeutics

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.